A structural basis for the allosteric regulation of non-hydrolysing UDP-GlcNAc 2-epimerases

EMBO Reports
Lucas M VellosoC Erec Stebbins

Abstract

The non-hydrolysing bacterial UDP-N-acetylglucosamine 2-epimerase (UDP-GlcNAc 2-epimerase) catalyses the conversion of UDP-GlcNAc into UDP-N-acetylmannosamine, an intermediate in the biosynthesis of several cell-surface polysaccharides. This enzyme is allosterically regulated by its substrate UDP-GlcNAc. The structure of the ternary complex between the Bacillus anthracis UDP-GlcNAc 2-epimerase, its substrate UDP-GlcNAc and the reaction intermediate UDP, showed direct interactions between UDP and its substrate, and between the complex and highly conserved enzyme residues, identifying the allosteric site of the enzyme. The binding of UDP-GlcNAc is associated with conformational changes in the active site of the enzyme. Kinetic data and mutagenesis of the highly conserved UDP-GlcNAc-interacting residues confirm their importance in the substrate binding and catalysis of the enzyme. This constitutes the first example to our knowledge, of an enzymatic allosteric activation by direct interaction between the substrate and the allosteric activator.

References

Sep 1, 1988·FEMS Microbiology Reviews·H M KuhnH Mayer
May 21, 1999·Science·O T KepplerM Pawlita
Apr 17, 2002·Accounts of Chemical Research·Martin E Tanner
Jun 24, 2004·Biochimica Et Biophysica Acta·Jomy Samuel, Martin E Tanner
May 1, 1997·Acta Crystallographica. Section D, Biological Crystallography·G N MurshudovE J Dodson
Sep 6, 2006·Journal of Bacteriology·Iharilalao DubailAlain Charbit

❮ Previous
Next ❯

Citations

Jun 13, 2012·Natural Product Reports·Shanteri SinghJon S Thorson
Jul 30, 2010·The Journal of Biological Chemistry·Søren W GerstingAnia C Muntau
Apr 18, 2013·PloS One·Raymond SchuchVincent A Fischetti
Jan 28, 2015·Journal of Molecular Biology·Ekaterina V FilippovaWayne F Anderson
Dec 14, 2011·Proteins·Chittaranjan TripathyBruce Randall Donald
Sep 24, 2015·Journal of Bacteriology·Megan Liszewski ZillaDominique Missiakas
Aug 31, 2016·Infection and Immunity·Lívia A AlvesRenata O Mattos-Graner
Mar 31, 2016·Journal of Biomolecular Screening·Yan HouMark A McCoy
Feb 9, 2017·MedChemComm·Sang-Yong Lee, Christa E Müller
Mar 7, 2017·Frontiers in Pharmacology·Sang-Yong LeeChrista E Müller
Nov 3, 2020·Acta Crystallographica. Section F, Structural Biology Communications·Nicholas K HurlburtAndrew J Fisher
May 16, 2019·Journal of Structural Biology·Erika Chang de Azevedo, Alessandro S Nascimento
Jul 16, 2008·Current Opinion in Chemical Biology·Alejandro Buschiazzo, Pedro M Alzari
Nov 10, 2009·International Journal of Medical Microbiology : IJMM·Guoqing XiaAndreas Peschel

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.